Achieving hepatitis B targets in Australia is cost-effective
The World Health Organization (WHO) has set specific hepatitis B elimination targets for 2030. These include:
- 90% of people living with chronic hepatitis B to be diagnosed
- 80% of people eligible for treatment to be treated.
In Australia, approximately a quarter of a million people are living with chronic hepatitis B, yet an estimated one in three are not diagnosed and only around 26% of those who are eligible for treatment (based on current treatment guidelines) are on therapy.
The cost and cost-effectiveness of scaling up to reach the national and WHO targets in Australia have not been measured previously. This brief report presents our estimates.
Download Report
Yinzong Xiao
Yinzong is a public health researcher and mathematical modeller at the Burnet Institute. She works on a variety of public health/health economic projects in infectious diseases and global health and has a special interest in public health problems concerning hepatitis B at both a regional and global level.
EMAIL Call